Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2013

West Howard, Oxnard Geoffrey R, Doebele Robert C

Abstract excerpt

Although the transition to molecularly defined patient subgroups in advanced non-small cell lung cancer (NSCLC) often leads to dramatic and prolonged responses to an inhibitor of an identified oncogenic mutation, acquired resistance eventually ensues. The optimal approach to management in that setting remains the subject of ongoing research, although it is possible to identify several points that distinguish it...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Design

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23714521
DOI: 10.14694/EdBook_AM.2013.33.e272
PMCID: PMC4142045

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.PMID 23714521Read ↗

Acquired resistance in oncogene-addicted non-small-cell lung cancer.Semantic proximity Read ↗

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.Semantic proximity Read ↗

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insightsSemantic proximity Read ↗

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.Semantic proximity Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs.Semantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Semantic proximity Read ↗

Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapiesSemantic proximity Read ↗

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.Semantic proximity Read ↗

Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.Semantic proximity Read ↗

Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.